top of page

BMS’ Ulcerative Colitis trial shows low efficacy

Bristol Myers Squibb (BMS) had been trialing deucravacitinib as an ulcerative colitis treatment, however, they have recently announced it failed to meet their primary and secondary efficacy goals.

During Phase II of the LATTICE-UC clinical trial, assessed the safety and efficacy of the treatment, and failed to meet the goals of clinical remission according to a 12 week May score.

The secondary goals of the trial looked at a clinical response via. Endoscopic response and histological improvement across the same timeline.

The treatment itself is an orally delivered drug, which is known as a selective tyrosine kinase 2 inhibitors. The treatment acts on TYK2 to hinder signaling in the body that is linked to various immune-mediated diseases, such as ulcerative colitis.

Moving forward, the treatment will be further explored in a Phase III trial aimed at using deucravacitinib as a treatment for psoriatic arthritis, which has previously proven to be effective.

The chief medical officer at BMS said in an interview with Clinical Trials arena, “While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases.”

The treatment still proved to be safe and tolerable, with no new reported adverse effects. The company is also running another Phase II trial to test a higher dose in patients with moderate to severe UC.

Want to Learn More?

In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient-perspective should be considered when designing studies to ensure that patient targets are met not only on time, but also on budget.

For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real time. The best part: these patients are already educated and prepared for the clinical trial process.

If you’d like to hear more about what we do, go here to read about what sets us apart, or here to read what our patients have to say about us.


bottom of page